ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,611,947 | -22.4% | 2,218,253 | +3.0% | 0.01% | -22.2% |
| Q2 2023 | $76,777,786 | +45.4% | 2,153,050 | +3.6% | 0.01% | +28.6% |
| Q1 2023 | $52,794,603 | +65854.5% | 2,078,527 | +5.3% | 0.01% | -36.4% |
| Q4 2022 | $80,047 | -99.9% | 1,973,551 | +4.6% | 0.01% | +22.2% |
| Q3 2022 | $62,378,000 | -4.3% | 1,887,397 | +1.9% | 0.01% | -10.0% |
| Q2 2022 | $65,186,000 | -23.6% | 1,851,377 | -0.2% | 0.01% | -9.1% |
| Q1 2022 | $85,308,000 | -29.1% | 1,854,931 | +2.1% | 0.01% | -26.7% |
| Q4 2021 | $120,394,000 | +7.7% | 1,815,900 | +1.4% | 0.02% | 0.0% |
| Q3 2021 | $111,773,000 | -25.4% | 1,790,377 | -1.0% | 0.02% | -28.6% |
| Q2 2021 | $149,804,000 | +28.6% | 1,808,802 | +3.0% | 0.02% | +16.7% |
| Q1 2021 | $116,474,000 | -5.6% | 1,756,510 | +9.2% | 0.02% | -14.3% |
| Q4 2020 | $123,402,000 | +87.5% | 1,608,273 | +5.2% | 0.02% | +61.5% |
| Q3 2020 | $65,805,000 | -2.0% | 1,528,228 | -1.7% | 0.01% | -7.1% |
| Q2 2020 | $67,152,000 | +54.0% | 1,554,456 | +2.6% | 0.01% | +27.3% |
| Q1 2020 | $43,605,000 | -76.0% | 1,515,643 | -47.1% | 0.01% | -42.1% |
| Q4 2019 | $181,708,000 | +389.7% | 2,864,722 | +117.6% | 0.02% | +111.1% |
| Q3 2019 | $37,107,000 | +9.2% | 1,316,785 | +2.7% | 0.01% | +12.5% |
| Q2 2019 | $33,993,000 | +59.3% | 1,282,786 | +10.3% | 0.01% | +33.3% |
| Q1 2019 | $21,335,000 | -13.8% | 1,162,703 | -41.7% | 0.01% | +50.0% |
| Q4 2018 | $24,750,000 | +40.0% | 1,992,916 | +116.1% | 0.00% | -20.0% |
| Q3 2018 | $17,677,000 | +48.7% | 922,163 | +5.5% | 0.01% | +25.0% |
| Q2 2018 | $11,885,000 | +161.4% | 873,912 | +38.6% | 0.00% | +300.0% |
| Q1 2018 | $4,546,000 | +105.1% | 630,631 | +4.7% | 0.00% | 0.0% |
| Q4 2017 | $2,216,000 | -17.4% | 602,346 | -2.8% | 0.00% | 0.0% |
| Q3 2017 | $2,683,000 | +196.1% | 619,730 | +10.7% | 0.00% | – |
| Q2 2017 | $906,000 | -26.1% | 559,727 | -15.6% | 0.00% | -100.0% |
| Q1 2017 | $1,226,000 | +23.3% | 663,062 | +3.4% | 0.00% | – |
| Q4 2016 | $994,000 | -71.7% | 641,408 | +34.1% | 0.00% | -100.0% |
| Q3 2016 | $3,516,000 | +58.6% | 478,392 | +14.8% | 0.00% | +100.0% |
| Q2 2016 | $2,217,000 | – | 416,784 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |